CALCIMEDICA INC Stock Price, News & Analysis

CalciMedica, a biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic illnesses, announced its inclusion in the Russell Microcap® Index. The inclusion will be effective from July 1, 2024, following the Russell U.S. Indexes annual reconstitution, which ranks the 4,000 largest U.S. stocks by market capitalization. This marks a significant milestone for CalciMedica, highlighting its growth since going public in Q1 2023. Russell indexes are key benchmarks for investment managers and institutional investors, representing $10.5 trillion in assets as of December 2023.

CalciMedica announced positive topline data from its Phase 2b CARPO trial evaluating Auxora™ in treating acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). The trial met its primary objective, showing a statistically significant dose response. Key findings include up to a 43.6% reduction in median time to solid food tolerance, a 61.7% reduction in severe organ failure, and a 100% reduction in hospital stays longer than 21 days. The trial demonstrated Auxora's safety and tolerability, with plans for a Phase 3 trial and an upcoming FDA meeting.

CalciMedica announced it will host a conference call on June 27, 2024, at 8:30 a.m. ET to discuss topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS). The clinical-stage biopharmaceutical company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses. Interested parties can join the call via a live webcast or dial-in numbers provided on CalciMedica's investor relations website. A webcast replay will be available post-event.

CalciMedica reported a significant quarter ending March 31, 2024, marked by the completion of enrollment for the Phase 2b CARPO trial for Auxora™ in acute pancreatitis (AP), with topline data expected in 2Q 2024.

Additionally, the KOURAGE Phase 2 trial for severe acute kidney injury (AKI) will start patient enrollment in 2Q 2024, with data expected in 2025. A related abstract will be presented at Digestive Disease Week (DDW) 2024.

Financially, the company completed a $54 million private placement, with $20.4 million received upfront and $33.1 million pending from warrant exercises. With $25.7 million in cash and equivalents, operations are funded into the second half of 2025. Total operating losses were $5.8 million for Q1, offset by a $5.6 million gain from warrant liability adjustment, resulting in a $0.1 million net income.

CalciMedica Inc. announces an upcoming presentation at Digestive Disease Week 2024 where collaborators from Cedars-Sinai will present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis. The presentation will highlight the similarities between the benefits of Auxora and those seen in COVID-19 pneumonia.